Previous close | 13.00 |
Open | 13.06 |
Bid | 0.00 x 800 |
Ask | 20.96 x 1100 |
Day's range | 13.03 - 13.16 |
52-week range | 11.43 - 13.22 |
Volume | |
Avg. volume | 160,472 |
Market cap | 461.542M |
Beta (5Y monthly) | 0.61 |
PE ratio (TTM) | 7.40 |
EPS (TTM) | 1.77 |
Earnings date | N/A |
Forward dividend & yield | 1.49 (11.34%) |
Ex-dividend date | 12 Apr 2024 |
1y target est | N/A |
BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) (5LB: FRA) ("BioVaxys" or "the Company"), is pleased to announce that it has further extended its research collaboration with The Ohio State University ("The Ohio State") for SARS-CoV-2, SARS-CoV-1, and pan-sarbecovirus vaccine research. This is the second twelve-month extension of the research collaboration between BioVaxys and the University since 2021.